Welcome  Guest  ! Sign Up Language
 
 
Home    Markets    Equity    Corporate Info    
Biocon Ltd.
NSE : BIOCON BSE : 532523 ISIN code : INE376G01013 Industry : Pharmaceuticals & Drugs House : Private  
Market Open - NSE
Rs. 652.05  
-5.6    -0.85%
Vol(000's) 3525.582
on 18-Jan-2019 12:00
 Day low
Day high 
 650
672.5 
 52 week low
52 week high 
 543.3
718 
BSE
Rs.651.10
-6.25    -0.95%
Market Open - BSE
Rs. 651.10  
-6.25    -0.95%
Vol(000's) 174.29
on 18-Jan-2019 12:00
 Day low
Day high 
 649.7
671.9 
 52 week low
52 week high 
 543.8
718.35 
NSE
Rs.652.05
-5.6    -0.85%
BSE NSE  
Technical Chart
1D   | 1M   | 3M   | 1Y  | 3Y  | 5Y
You need to upgrade your Flash Player
 
 Stock Summary
Prev.Close(Rs.)  657.35
Today's Open(Rs.)  660.00
Trade Value  115422963
Volume  174290
Divident Yield(%)  0.15
TTM EPS (Rs.)  7.75
P/E Ratio  83.99
Book Value(Rs.)  117.12
Face Value(Rs.)  5
MCap(Rs.in Mn)  390660.00
 
 Ratio
Price/Earnings(TTM)  83.99
Price/Sales(TTM)  14.90
Price/Book(MRQ)  5.56
PAT Margin  9.83
ROCE  4.53
 Company News    Previous News
Biocon, Mylan’s joint product Ogivri gets approval in EU
12/19/2018 00:00 Hrs IST

Biocon and Mylan’s jointly developed product -- Ogivri, a biosimilar Trastuzumab, has been approved in the European Union (EU). The European Commission has granted Marketing Authorization for Ogivri to the company’s partner Mylan.

The European Medicines Ag...

 
Biocon trades higher on the bourses
USFDA concludes inspection at Biocon's A...
More>
 Financials
  QUARTERLY Sep 18 ANNUAL 18
Net Profit (Rs.Mn) 1198 2385
Gross Profit (Rs.Mn) 1409 3058
Operating Profit (Rs.Mn) 1476 4429
Net Sales (Rs.Mn) 7089 24255
 
 PAT Growth
Chart.
 
 Rolling Forward P/E (EOD)
12 Months Rolling Forward P/E (X)
 Competitors (Rs. in Crore) 
Sumpoorna's Analysis
NameChartYear EndPE(X)ROE(%)Earnings Growth1-Year ReturnOperating EfficiencyAsset Use EfficiencyEquity Leverage
       PAT MarginROCEAsset Turnover RatioDebt/Equity
Biocon 20180383.993.62-84.6920.669.834.530.320.02
Industry Average - - 31.86 14.49-96.627.9914.5418.130.660.27
Aurobindo Pharma 20180333.2319.686.2119.3117.5919.020.710.37
Cipla 20180325.6310.9650.51-15.5012.8314.030.700.01
Lupin 20180326.718.91-57.24-6.4013.3311.720.550.00
Cadila Healthcare 20180323.2715.1964.80-20.4318.7315.470.460.37
 
 Event Calendar
Bonus Issue | Book Closure |
Board Meeting
 
Record DateBonus Ratio
15/Jun/172 : 1
11/Sep/081 : 1
28/Nov/0323.5 : 1
19/Dec/962 : 1

Sumpoorna About Us
Customer Service
Our Offering
Open an account
Channel Partners
Contact Us
Career

Markets News
Equity
Derivatives
Commodities
Currency
IPOs
Mutual Fund

Quick Links EasyPolicy.com NSE
BSE
SEBI
MCX
FMC
RBI

Navigate Login - BackOffice
Login - Now Online
Fund Transfer
Download
Sitemap
Legal

ToolsPortfolio Tracker
Stock Watch
Advanced Charting



Refer A Friend
Facebook
Twiter
Blog
Linkedin
ATTENTION INVESTORS : "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors"
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
SEBI REGI NO : NSE CASH : INB231429037 | NSE F&O : INF231429037 | NSE CURR : INE231429037 | BSE CASH : INB011429033 | BSE F&O : INF011429033 | MCX : INZ000037836 |MEMBER CODE : NSE : 14290 | BSE : 6404 | MCX CODE: 46150| DP Sebi Regn. No: IN-DP-CDSL-665-2012
The Stock Exchange, Mumbai is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time. The Stock Exchange, Mumbai is not answerable, responsible or liable for any information on this Website or for any services rendered by our employees, our servants, and us.
Copyright © 2014 SUMPOORNA Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.